NCT02523014

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2015-09-28Est. Completion: 2027-01-01

Enrollment target: 124 participants

Locations

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
Alaska Women's Cancer Care, Anchorage, Alaska, United States
Anchorage Oncology Centre, Anchorage, Alaska, United States
Katmai Oncology Group, Anchorage, Alaska, United States
Providence Alaska Medical Center, Anchorage, Alaska, United States
Kingman Regional Medical Center, Kingman, Arizona, United States
Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Arizona Oncology Services Foundation, Scottsdale, Arizona, United States
Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States

Meningioma

The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progres…

Miami, United StatesEst. completion Feb 29, 2028

Recurrent Meningioma

This phase I/II tests the safety, side effects, best dose and how well giving RYZ101 works for the treatment of patients…

Columbus, United StatesEst. completion Dec 31, 2026

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.